FSA
SAGE

Franklin Street Advisors’s Sage Therapeutics SAGE Stock Holding History

Franklin Street Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-7,650
Closed -$241K – 220
2014
Q3 		$241K Buy
+7,650
New +$222K 0.05% 207

Other funds holding SAGE

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Franklin Street Advisors's SAGE Position: Q4 2014 in Review

Franklin Street Advisors sold out of Sage Therapeutics (SAGE) in Q4 2014, closing a stake of 7,650 shares — an estimated $241K sold.

Franklin Street Advisors first reported a position in SAGE in Q3 2014 and held it in 1 quarter. The position peaked at $241K in Q3 2014. 73 funds tracked by Wall St. Rank hold SAGE as of Q4 2014.

  • Franklin Street Advisors reported no remaining Sage Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Franklin Street Advisors sold 7,650 Sage Therapeutics shares in Q4 2014, an estimated $241K.
  • Franklin Street Advisors first reported a position in Sage Therapeutics in Q3 2014 and held it in 1 quarter.
  • Franklin Street Advisors's Sage Therapeutics position peaked at $241K in Q3 2014.
  • 73 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2014.

Based on Franklin Street Advisors's 13F filing for Q4 2014, filed 9 Jan 2015.